Evidence map›Paper›PMID 25203057›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2015

Circulating mannan-binding lectin, M-, L-, H-ficolin and collectin-liver-1 levels in patients with acute liver failure.

Tea L Laursen, Thomas D Sandahl, Sidsel Støy, Frank V Schiødt, William M Lee, Hendrik Vilstrup, Steffen Thiel, Henning Grønbaek, US Acute Liver Failure Study Group

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00518440 (A Multi-Center Trial to Study Acute Liver Failure in Adults), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00518440 completednot on this map

A Multi-Center Trial to Study Acute Liver Failure in Adults

TypeobservationalSponsorWilliam LeeRan1998 to 2019Enrolled3,488ConditionsAcute Liver Failure, Fulminant Hepatic Failure, Acute Liver Injury
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Role of Complement in Liver Diseases.Seminars in liver disease · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Decreased expression ofCancer management and research · 2018
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Tea L LaursenDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Thomas D Sandahl
Sidsel Støy
Frank V Schiødt
William M Lee
Hendrik Vilstrup
Steffen Thiel
Henning Grønbaek
US Acute Liver Failure Study Group
Aarhus University Hospital · DKAarhus University · DKBispebjerg Hospital · DKThe University of Texas Southwestern Medical Center · US

Funding

A Multi-Center Study of Acute Liver Failure in AdultsU01DK058369 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI DURKALSKI, VALERIE L, FONTANA, ROBERT J · 2005 to 2019
$27.4M
NIDDK NIH HHS U01 DK058369NIDDK NIH HHS U01-DK-58369
6 · The paper itself

Abstract

BACKGROUND &

aimsThe complement system is activated in liver diseases including acute liver failure (ALF); however, the role of the lectin pathway of complement has scarcely been investigated in ALF. The pathway is initiated by soluble pattern recognition molecules: mannan-binding lectin (MBL), M-, L-, and H-ficolin and collectin-liver-1 (CL-L1), which are predominantly synthesized in the liver. We aimed to study lectin levels in ALF patients and associations with clinical outcome.

methodsSerum samples from 75 patients enrolled by the US ALF Study Group were collected on days 1 and 3. We included 75 healthy blood donors and 20 cirrhosis patients as controls. Analyses were performed using sandwich-type immunoassays (ELISA, TRIFMA).

resultsAt day 1, the MBL level in ALF patients was 40% lower compared with healthy controls {[median (interquartile range) 0.72 μg/ml(0.91) vs. 1.15 (1.92)(P = 0.02]}, and increased significantly by day 3 [0.83 μg/ml(0.94)(P = 0.01)]. The M-ficolin level was 60% lower [0.54 μg/ml(0.50) vs. 1.48(1.01)(P < 0.0001)]. The CL-L1 level at day 1 was slightly higher compared with healthy controls [3.20 μg/ml(2.37) vs. 2.64(0.72)(P = 0.11)]; this was significant at day 3 [3.35(1.84)(P = 0.006)]. H- and L-ficolin levels were similar to healthy controls. Spontaneous ALF survivors had higher levels of MBL at day 1 [0.96 μg/ml(1.15) vs. 0.60(0.60)(P = 0.02)] and lower levels of L-ficolin by day 3 compared with patients who died or were transplanted [1.61 μg/ml(1.19) vs. 2.17(2.19)(P = 0.02)].

conclusionWe observed significant dynamics in lectin levels in ALF patients, which may suggest they play a role in ALF pathogenesis. High MBL and low L-ficolin levels are associated with survival.

Indexed as

AdultAgedCase-Control StudiesCollectinsEnzyme-Linked Immunosorbent AssayFemaleFicolinsGlycoproteinsHumansLectinsLiverLiver Failure, AcuteMaleMannose-Binding LectinMiddle AgedSystemic Inflammatory Response SyndromeCOLEC10 protein, humanCollectinsFCN3 protein, humanFicolinsGlycoproteinsLectinsMannose-Binding Lectinacute liver failurecollectin-liver-1complement systemficolinsmannan-binding lectinthe lectin pathway

Identifiers

PMID25203057
PMCPMC4329085
OpenAlexW2046698221

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.